This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
Neurosteroid DHEA, produced by neurons and glia, affects multiple processes in the brain, including neuronal survival and neurogenesis during development and in aging. However no specific receptor has been reported to date for this important neurosteroid. We provide evidence that DHEA binds with high affinity to pro-survival TrkA and pro-death p75NTR membrane receptors of neurotrophin NGF, acting as a neurotrophic factor: 1) the anti-apoptotic effects of DHEA were reversed by siRNA against TrkA, or by a specific TrkA inhibitor, 2) [3H]DHEA displacement experiments showed that DHEA bound with high affinity on membranes isolated from HEK293 cells transfected with the cDNAs of TrkA and p75NTR receptors (IC50: 0,9 and 5.6 nM respectively). Membrane binding of DHEA on HEK293TrkA and HEK293p75NTR cells was also shown with flow cytometry and immunofluorecence microscopy, using the membrane impermeable DHEA-BSA-FITC conjugate, 3) immobilized DHEA pulled down recombinant and naturally expressed TrkA and p75NTR receptors, 4) DHEA induced TrkA phosphorylation, and NGF receptor-mediated signaling; Shc, Akt, and ERK1/2 kinases down-stream to TrkA receptors and TRFA6, RIP2 and RhoGDI effectors of p75NTR receptors, 5) DHEA rescued from apoptosis TrkA receptor positive sensory neurons of dorsal root ganglia in NGF null embryos and compensated NGF in rescuing from apoptosis NGF receptor positive sympathetic neurons of embryonic superior cervical ganglia. Our findings suggest that DHEA and NGF cross-talk via their binding to NGF receptors to afford brain shaping and maintenance during development. Phylogenetic findings on the evolution of neurotrophins, their receptors and CYP17, the enzyme responsible for DHEA biosynthesis, combined with our data support the hypothesis that DHEA served as a phylogenetically ancient neurotrophic factor.
Dehydroepiandrosterone (DHEA) is a steroid, produced in adrenals, in neurons and in glia . The physiological role of brain DHEA appears to be local i.e. paracrine, while that produced from adrenals, which represents the almost exclusive source of circulating DHEA, is systemic. The precipitous decline of both brain and circulating DHEA with advancing age has been associated to aging-related neurodegenerative diseases [1,2]. It is experimentally supported that DHEA protects neurons against noxious conditions [3-6]. DHEA exerts its multiple pro-survival effects either directly modulating at micromolar concentrations ï§ï€aminobutiric acid type A (GABAA), N-methyl-D-aspartate (NMDA) or sigma1 receptors, or following its conversion to estrogens and androgens. We have recently shown that nanomolar concentrations of DHEA protect sympathoadrenal PC12 cells from apoptosis . PC12 cells do not express functional GABAA or NMDA receptors and cannot metabolize DHEA to estrogens and androgens . The anti-apoptotic effect of DHEA in PC12 cells is mediated by highly affine (Kd: 1 nM) specific membrane binding sites . Activation of DHEA membrane binding sites results in an acute but transient sequential phosphorylation of the pro-survival MEK/ERK kinases which, in turn, activate transcription factors CREB and NFï«B, which afford the transcriptional control of anti-apoptotic Bcl-2 proteins. In parallel, activation of DHEA membrane binding sites induces the phosphorylation of PI3K/Akt kinases, leading to phosphorylation/deactivation of the pro-apoptotic Bad protein, and protection of PC12 cells from apoptosis .
In fact, the anti-apoptotic pathways in sympathoadrenal cells initiated by DHEA at the membrane level strikingly resemble those sensitive to neurotrophin nerve growth factor. NGF, promotes survival and rescuing from apoptosis of neural crest deriving sympathetic neurons (including their related sympathoadrenal cells), and sensory neurons involved in noniception. NGF binds with high affinity (Kd: 0.01 nM) to transmembrane tyrosine kinase TrkA receptor and with lower affinity (Kd: 1.0 nM) to p75NTR receptor, a membrane protein belonging to TNF receptor superfamily . In the presence of TrkA receptors, p75NTR participates in the formation of high affinity binding sites and enhances NGF responsiveness leading to cell survival signals. In the absence of TrkA, p75NTR generates cell death signals. Indeed, docking of TrkA by NGF initiates receptor dimerization, and phosphorylation of cytoplasmic 490 and 785 tyrosine residues on the receptor. Phosphotyrosine-490 interacts with Shc and other adaptor proteins resulting in activation of PI3K/Akt and MEK/ERK signaling kinase pathways . These signals lead to the activation of prosurvival transcription factors CREB and NFï«B, the subsequent production of anti-apoptotic Bcl-2 proteins and prevention of apoptotic cell death of sympathetic neurons and sympathoadrenal cells, including PC12 cells .
Intrigued by the similarities in the prosurvival signaling of DHEA and NGF, both initiated at the membrane level, we set out to examine in the present study whether the anti-apoptotic effects of DHEA are mediated by NGF receptors. To address this issue we employed a multifaceted approach designing an array of specific experiments. We used RNA interference (RNAi) to define the involvement of TrkA and p75NTR receptors in the anti-apoptotic action of DHEA. We assessed membrane binding of DHEA in HEK293 cells transfected with the TrkA and p75NTR plasmid cDNAs, using binding assays, confocal laser microscopy and flow cytometry. To investigate the potential direct physical interaction of DHEA with NGF receptors we tested the ability of immobilised DHEA to pull-down recombinant or naturally expressed TrkA and p75NTR receptors. Finally, we examined the ability of DHEA to rescue from apoptosis NGF receptor sensitive dorsal root ganglia sensory neurons of NGF null mice, and NGF deprived rat superior cervical ganglia sympathetic neurons in culture . We provide evidence that DHEA directly binds to NGF receptors to protect neuronal cells against apoptosis, acting as a neurotrophic factor.
RNA interference against TrkA receptors reverses the anti-apoptotic effect of DHEA.
To test the involvement of NGF receptors in the anti-apoptotic effect of DHEA in serum deprived PC12 cells we have used the RNAi technology. A combination of three different sequences of siRNAs for TrkA and two different shRNAs for p75NTR transcripts  were selected. The effectiveness of si/shRNAs was shown by the remarkable decrease of TrkA and p75NTR protein levels in PC12 cells, observed by immunobloting analysis, using GAPDH as reference standard (Figure 1b). Scrambled siRNAs were ineffective in decreasing TrkA and p75NTR protein levels and did not significantly alter the effect of DHEA (data not shown). FACS analysis of apoptotic cells (stained with Annexin V) has shown that DHEA and membrane impermeable DHEA-BSA conjugate at 100 nM diminished the number of apoptotic cells in serum deprived PC12 cell cultures from 53.5Â±17.6% increase of apoptosis in serum free condition (control) to 6Â±1.4% and 13Â±5.2%, respectively (n:8, P<0.01 versus control) (Figure 1a). Decreased TrkA expression in serum-deprived PC12 cells with siRNAs resulted in the almost complete reversal of the anti-apoptotic effect of DHEA and DHEA-BSA conjugate (Figure 1a). Co-transfection of serum deprived PC12 cells with the si/shRNAs for TrkA and p75NTR receptors did not modify the effect of the TrkA deletion alone. Furthermore, transfection of serum deprived PC12 cells with the shRNAs against p75NTR receptor alone did not significantly alter the anti-apoptotic effect of DHEA, suggesting that the anti-apoptotic effect of DHEA is primarily afforded by TrkA receptors.
Transfection of serum-deprived PC12 cells with the siRNAs against the TrkA transcript fully annulled the ability of DHEA to maintain elevated the levels of anti-apoptotic Bcl-2 protein (Figure 1b). Again, transfection with the shRNA against p75NTR receptor alone did not significantly affect Bcl-2 induction by DHEA, further supporting the hypothesis that TrkA is the main mediator of the anti-apoptotic effect of DHEA in this system.
It appears that the ratio of TrkA and p75NTR receptors determines the effect of DHEA on cell apoptosis and survival. Indeed, both NGF and DHEA induced apoptosis of nnr5 cells, a clone of PC12 cell line known to express only pro-death p75NTR receptors (Figure 1c), confirming the pro-apoptotic function of this receptor. Blockade of p75NTR expression by shRNA almost completely reversed the pro-apoptotic effect of both agents. The anti-apoptotic effect of NGF and DHEA was remarkably restored after transfection of nnr5 cells with the TrkA cDNA, the efficacy of reversal being proportionally dependent on the amount of transfected TrkA cDNA (Figure 1c). DHEA was also controlling the response of NGF receptor positive cells, by regulating TrkA and p75NTR receptor levels, mimicking NGF. Serum deprived PC12 cells were exposed to 100 nM of DHEA or 100 ng/ml of NGF for 12, 14 and 48 hours, TrkA and p75NTR protein levels were measured in cell lysates with immunoblotting, using specific antibodies against TrkA and p75NTR proteins and were normalized against GAPDH. Both NGF and DHEA significantly increased pro-survival TrkA receptor levels in the time frame studied, i.e. from 12 to 48 hours (n:5, P<0.01) (Figure 1d). Furthermore, DHEA and NGF significantly decreased p75NTR receptor levels between 24 to 48 hours of exposure (n:5, P<0,01).
We have also tested the anti-apoptotic effects of DHEA in neural crest deriving superior cervical ganglia (SCG), a classical NGF/TrkA sensitive mammalian brain tissue, containing primarily one class of neurons, principal sympathetic neurons. Indeed, NGF and TrkA receptors are absolutely required for SCG sympathetic neuron survival during late embryogenesis and early postnatal development [13, 15]. TrkC receptors are barely detectable after E15.5, and no significant TrkB receptors are present in the SCG at any developmental stage . Organotypic cultures of rat SCG at P1 were incubated in the presence of 100ng/ml NGF, or in the same medium as above but lacking NGF and containing a polyclonal rabbit anti-NGF-neutralizing antiserum in the absence or the presence of 100nM DHEA. Withdrawal of NGF resulted in a rapid degeneration of ganglia, effect which was completely reversed in the presence of DHEA (Figure 2a). We repeated these experiments using dispersed sympathetic neurons in culture, isolated from rat SCGs at P1. Deprivation of NGF strongly increased the number of apoptotic sympathetic neurons stained with Annexin V, while DHEA effectively compensated NGF by decreasing the levels of apoptotic neurons, effect which was blocked by a specific TrkA inhibitor thus, suggesting the involvement of TrkA receptors as the main mediator of the anti-apoptotic action of DHEA (Figure 2b). Moreover, inhibition of p75NTR by a specific antibody (MAB365R, Millipore) against its extracellular domain, strongly induced a DHEA- or NGF-mediated anti-apoptotic effect, clearly indicating that p75NTR receptor serves a pro-apoptotic role in SCGs also, effect which is apparent only in the absence of TrkA receptor, as it was also shown in nnr5 cells.
[3H]DHEA binds with high affinity to HEK293TrkA and HEK293p75NTR cell membranes.
We have previously shown the presence of specific DHEA binding sites to membranes isolated from PC12, primary human sympathoadrenal, and primary rat hippocampal cells, with Kd 0.9, 0.1 and 0.06 nM, respectively . The presence of DHEA-specific membrane binding sites on PC12 cells has been confirmed by flow cytometry and confocal laser microscopy of cells stained with the membrane impermeable DHEA-BSA-FITC conjugate. In contrast to estrogens, glucocorticoids and androgens displaced [3H]DHEA from its membrane binding sites, acting as pure antagonists by blocking theÂ anti-apoptotic effect of DHEA in serum deprived PC12 cells9. In the present study, we repeated this series of experiments using membranes isolated from HEK293 cells transfected with the plasmid cDNAs of TrkA or p75NTR receptors. Homologous [3H]DHEA displacement experiments with unlabeled DHEA showed the presence of specific DHEA binding on membranes from both HEK293TrkA and HEK293p75NTR cells with IC50 0.9 and 5.6 nM, respectively (Figure 3a). No specific binding of [3H]DHEA was observed on membranes isolated from non-transfected HEK293 cells or from HEK293 cells transfected with the empty vectors.
The selectivity of DHEA binding on HEK293TrkA and HEK293p75NTR cell membranes was examined by performing heterologous [3H]DHEA displacement experiments using a number of non-labeled steroids or NGF. Binding of [3H]DHEA on membranes isolated from both HEK293TrkA and HEK293p75NTR cells was effectively displaced by NGF (IC50: 0.08 and 1.1 nM, respectively) (Figure 3a). NGF was also effectively displacing [3H]DHEA binding on membranes isolated from PC12 cells (IC50: 0.8 nM, data not shown). Estradiol failed to displace [3H]DHEA from its binding on membranes from HEK293TrkA and HEK293p75NTR cells at concentrations ranging from 0.1 to 1000 nM. In contrast, displacement of [3H]DHEA binding on membranes from both HEK293TrkA and HEK293p75NTR cells was shown by testosterone (Testo) (IC50: 3.3 and 7.4 nM, respectively). Glucocorticoid dexamethasone (Dex) effectively competed [3H]DHEA binding on membranes from HEK293TrkA (IC50: 10.5 nM) but was ineffective in displacing DHEA binding on membranes from HEK293p75NTR cells. Homologous [125I]NGF displacement experiments with unlabeled NGF confirmed the presence of specific NGF binding on membranes from both HEK293TrkA and HEK293p75NTR cells with IC50 0.03 and 1.7 nM respectively (data not shown). It is of note that in contrast to unlabeled NGF, DHEA was unable to displace binding of [125I]NGF on membranes isolated from HEK293TrkA and HEK293p75NTR transfectants.
DHEA-BSA-FITC conjugate stains HEK293TrkA and HEK293p75NTR cell membranes.
Incubation of PC12 cells with the membrane impermeable, fluorescent DHEA-BSA-fluorescein conjugate results in a specific spot-like membrane fluorescent staining . In the present study, we have tested the ability of DHEA-BSA-FITC conjugate to stain HEK293TrkA and HEK293p75NTR transfectants. Fluorescence microscopy analysis revealed that DHEA-BSA-FITC clearly stained the membranes of HEK293TrkA and HEK293p75NTR cells (Figure 3b). No such staining was found in non-transfected HEK293 cells (data not shown) or in HEK293 cells transfected with the vectors empty of TrkA and p75NTR cDNAs (Figure 3b). Furthermore, BSA-FITC conjugate was ineffective in staining both transfectants (data not shown). We have further confirmed the presence of membrane DHEA-BSA-FITC staining of HEK293TrkA and HEK293p75NTR cells with flow cytometry (FACS) analysis (Figure 3c). Specific staining was noted in both transfectants. No such staining was seen in non-transfected HEK293 cells (data not shown) or in HEK293 cells transfected with the empty vectors (Figure 3c). In both fluorescence microscopy and FACS experiments membrane staining of TrkA or p75NTR proteins in HEK293TrkA and HEK293p75NTR cells was also shown using specific antibodies for each protein (Figures 3b, 3c).
Immobilised DHEA pulls down TrkA and p75NTR receptors.
Our binding assays with radiolabeled DHEA suggest that DHEA physically interacts with NGF receptors. To test this hypothesis we covalently linked DHEA-7-O-(carboxymethyl) oxime DHEA-7-CMO) to polyethylene glycol amino resin (NovaPEG amino resin) and we tested the ability of immobilized DHEA to pull down TrkA and p75NTR proteins. Precipitation experiments and western blot analysis of precipitates with specific antibodies against TrkA and p75NTR proteins (Figure 4) showed that immobilized DHEA effectively precipitated recombinant TrkA and p75NTR proteins. Similar results were obtained when cell extracts isolated from HEK293 cells transfected with TrkA and p75NTR cDNAs, PC12 cells and whole rat brain were treated with immobilised DHEA (Figure 4, panels marked with A). No precipitation of TrkA and p75NTR proteins was shown with polymer-supported DHEA-7-CMO incubated with cell extracts from untransfected HEK293 cells or HEK293 cells transfected with the empty vectors. A control experiment was performed with NovaPeg amino resin (no DHEA-7-CMO present) which was found ineffective in precipitating TrkA and p75NTR proteins (Figure 4). The presence of TrkA and p75NTR receptors in HEK293TrkA and HEK293p75NTR transfectants and in PC12 and fresh rat brain was confirmed with western blot analysis using specific antibodies against TrkA and p75NTR proteins and GAPDH as reference standard (Figure 4, panels marked with B).
DHEA induces TrkA- and p75NTR-mediated signaling.
Previous findings have shown that NGF controls the responsiveness of sensitive cells through induction of TrkA phosphorylation and regulation of the levels of each own receptors . We compared the ability of NGF and DHEA to induce phosphorylation of TrkA in HEK293 cells transfected with the cDNAs of TrkA receptors. HEK293TrkA transfectants were exposed for 10 and 20 min to 100 nM of DHEA or 100 ng/ml of NGF, and cell lysates were immunoprecipitated with anti-tyrosine antibodies and analyzed by western blotting, using specific antibodies against TrkA receptors. Both NGF and DHEA strongly increased phosphorylation of TrkA as early as 10 min, effect which was also maintained at 20 min (Figure 5a). We also tested the effects of DHEA and NGF in PC12 cells, endogenously expressing TrkA receptors. Naive or siRNATrkA transfected PC12 cells were incubated for 10 min with DHEA or NGF, and cell lysates were analyzed with western blotting, using specific antibodies against Tyr490-phosphorylated TrkA and total TrkA. Both NGF and DHEA strongly induced the phosphorylation of TrkA in naive PC12 cells, effects which were diminished in siRNATrkA transfected PC12 cells (Figure 5a). The stimulatory effect of DHEA on TrkA phosphorylation might be due to an increase of NGF production. To test this hypothesis, we measured with ELISA the levels of NGF in culture media of HEK293 and PC12 cells exposed for 5 to 30 min to 100 nM of DHEA. NGF levels in culture media of control and DHEA-treated HEK293 and PC12 cells were undetectable, indicating that DHEA-induced TrkA phosphorylation was independent of NGF production.
We compared the ability of NGF and DHEA to induce phosphorylation of TrkA-sensitive Shc, ERK1/2 and Akt kinases. Serum deprived naive or siRNATrkA transfected PC12 cells were incubated for 10 min with 100 nM DHEA or 100 ng/ml NGF and cell lysates were analyzed with western blotting, using specific antibodies against the phosphorylated and total forms of kinases mentioned above. Both DHEA and NGF strongly increased phosphorylation of Shc, ERK1/2 and Akt kinases in naive PC12 cells, effects which were almost absent in siRNATrkA transfected PC12 cells, suggesting that both DHEA and NGF induce Shc, ERK1/2 and Akt phosphorylation via TrkA receptors (Figure 5a).
The effectiveness of DHEA to promote the interaction of p75NTR receptors with its effector proteins TRAF6, RIP2 and RhoGDI was also assessed. It is well established that NGF induces the association of p75NTR receptors with TNF receptor-associated factor 6 (TRAF6), thus, facilitating nuclear translocation of transcription factor NFÎºB . Furthermore, p75NTR receptors associate with receptor-interacting protein 2 (RIP2) in a NGF-dependent manner . RIP2 binds to the death domain of p75NTR via its caspase recruitment domain (CARD), conferring nuclear translocation of NFÎºB. Finally, naive p75NTR interacts with RhoGDP dissociation inhibitor (RhoGDI), activating small GTPase RhoA . In that case, NGF binding abolishes the interaction of p75NTR receptors with RhoGDI, thus, inactivating RhoA. We co-transfected HEK293 cells with the plasmid cDNAs of p75NTR and of each one of the effectors TRAF6, RIP2 or RhoGDI, tagged with the flag (TRAF6) or myc (RIP2, RhoGDI) epitopes. Transfectants were exposed to 100 nM DHEA or 100 ng/ml NGF, and lysates were immunoprecipitated with antibodies against flag or myc, followed by immunoblotting with p75NTR specific antibodies. Both DHEA and NGF efficiently induced the association of p75NTR with effectors TRAF6 and RIP2, while facilitated the dissociation of RhoGDI from p75NTR receptors (Figure 5b).
DHEA reverses the apoptotic loss of TrkA positive sensory neurons in dorsal root ganglia of NGF null mouse embryos.
NGF null mice have less sensory neurons in dorsal root ganglia due to their apoptotic loss . Heterozygous mice for the NGF deletion were interbred to obtain mice homozygous for the NGF gene disruption. The mothers were treated daily with an intraperitoneal injection of DHEA (2 mg) or vehicle (4.5% ethanol in 0.9% saline). Embryos were collected at E14 day of pregnancy and sections were stained for Caspase 3 and Fluoro jade C, markers of apoptotic and degenerative neurons, respectively. ngf-/- embryos at E14 showed a dramatic increase in the number of Fluoro Jade C and Caspase 3 positive neurons in the DRG compared to the ngf+/- embryos (Figures 6a, 6b). DHEA treatment significantly reduced Fluoro Jade C and Caspase 3 positive neurons in the DRG to levels of ngf+/- embryos. Furthermore, TrkA and TUNEL double staining of DRGs has shown that in ngf+/- embryos, numbers of TUNEL-positive apoptotic neurons were minimal, while TrkA positive staining was present in a large number of neuronal cell bodies of the DRG and their collaterals were extended within the marginal zone to the most dorsomedial region of the spinal cord. On the contrary, in DRG of ngf-/- embryos levels of TUNEL-positive apoptotic neurons were dramatically increased while TrkA neuronal staining was considerably decreased and DRG collaterals of the dorsal funiculus were restricted in the dorsal root entry zone (Figure 6c). DHEA treatment resulted in a significant increase of TrkA positive staining and the extension of TrkA staining within the marginal zone to the most dorsomedial region of the spinal cord similarly to the ngf+/- embryos (Figure 6d), while staining of TUNEL-positive apoptotic neurons was decreased to levels shown in ngf+/- embryos.
DHEA exerts multiple actions in the central and peripheral nervous system, however no specific receptor has been reported to date for this neurosteroid. Most of its actions in the nervous tissue were shown to be mediated via modulation, at micromolar concentrations, of membrane neurotransmitter receptors, such as NMDA, GABAA and sigma1 receptors. DHEA may also influence brain function by direct binding at micromolar concentrations to dendritic brain microtubule-associated protein MAP2C . In the present study we provide evidence that DHEA binds with high affinity to NGF receptors. This is the first report showing a highly affine, direct binding of a steroid to neurotrophin receptors. Displacement binding assays of [3H]DHEA on membranes isolated from HEK293 cells transfected with the cDNAs of TrkA and p75NTR receptors showed that DHEA binds with high affinity to both membranes (IC50 0.9 and 5.6 nM, respectively). Non-radioactive NGF effectively displaced [3H]DHEA binding to both membrane preparations, with IC50 values 0.08 nM for HEK293TrkA cells and at 1.1 nM for HEK293p75NTR cells, respectively. Furthermore, pull down experiments using DHEA covalently immobilized on NovaPEG amino resin suggest that DHEA binds directly to TrkA and p75NTR proteins. Indeed, polymer-supported DHEA-7-CMO effectively pulled down recombinant TrkA and p75NTR proteins, and precipitated both proteins from extracts prepared from cells expressing both receptors (HEK293TrkA, HEK293p75NTR and PC12 cells and freshly isolated rat brain). Interestingly, DHEA was unable to effectively displace binding of [125I]NGF on membranes isolated from HEK293TrkA and HEK293p75NTR transfectants. It is possible that dissociation of binding of peptidic NGF from its receptors lasts longer due to the multiple sites of interaction within the binding cleft of this large peptidic molecule compared to smaller in volume steroid. The domains of TrkA and p75NTR proteins involved in DHEA binding were not defined in the present study. Mutagenesis assays combined with NMR spectroscopy are planned to map the domains of both receptors related to DHEA binding. However, our findings that DHEA mimics NGF in binding to both TrkA and p75NTR receptors and that NGF effectively displaces DHEA binding to both receptors, support the hypothesis that NGF and DHEA share the same binding sites. Other small molecules, like antidepressant amitriptyline and gamboge's natural extract gambogic amide bind, although with much lower affinity compared to DHEA (Kd 3ïM and 75 nM, respectively), in the extracellular and the cytoplasmic juxtamembrane domains of TrkA receptor [22,23].
Our findings suggest that binding of DHEA to NGF receptors is functional, mediating its anti-apoptotic effects. Indeed, blocking of TrkA expression by RNAi almost completely reversed the ability of DHEA to protect PC12 cells from serum deprivation-induced apoptosis and to maintain elevated levels of the anti-apoptotic Bcl-2 protein. Additionally, in dispersed primary sympathetic neurons in culture, DHEA effectively compensated NGF deprivation by decreasing the levels of apoptotic neurons, effect which was reversed by a specific TrkA inhibitor further supporting the involvement of TrkA receptors in the anti-apoptotic action of DHEA. Finally, DHEA effectively rescued from apoptosis TrkA-positive dorsal root ganglia sensory neurons of NGF null mouse embryos.
It appears that the decision between survival and death among DHEA-responsive cells is determined by the ratio of TrkA and p75NTR receptors. In fact, DHEA and NGF induced apoptosis of nnr5 cells, a clone of PC12 cells expressing only pro-death p75NTR receptors. The pro-death effects of both agents were completely blocked by p75NTR shRNA and were remarkably restored after transfection of nnr5 cells with the TrkA cDNA. It is of note that during brain development the ratio of TrkA to p75NTR varies tempospatially . Thus, the ability of DHEA to act in a positive or negative manner on neuronal cell survival may depend upon the levels of the two receptors during different stages of neuronal development.
Binding of DHEA on both TrkA and p75NTR receptors was effectively competed by testosterone (IC50: 3.3 and 7.4 nM, respectively) while synthetic glucocorticoid dexamethasone displaced DHEA binding only to pro-survival TrkA receptors (IC50: 10.5 nM). In a previous study we had shown that both steroids effectively displaced DHEA from its specific membrane binding sites of sympathoadrenal cells, acting as DHEA antagonists by blocking its anti-apoptotic effect and the induction of anti-apoptotic Bcl-2 proteins . Our findings suggest that testosterone and glucocorticoids may act as neurotoxic factors by antagonizing endogenous DHEA and NGF for their binding to NGF receptors [25,26]. Glucocorticoids show a bimodal effect on hippocampal neurons causing acutely an increase in performance of spatial memory tasks, while chronic exposure has been associated with decreased cognitive performance, and neuronal atrophy . Acute administration of glucocorticoids results in a glucocorticoid receptor-mediated phosphorylation and activation of hippocampal TrkB receptors, exerting trophic effects on dentate gyrus hippocampal neurons , via an increase in the sensitivity of hippocampal cells to neurotrophin BDNF, the endogenous TrkB ligand known to promote memory and learning . However, overexposure to glucocorticoids during prolonged periods of stress is detrimental to central nervous system neurons, especially in aged animals, affecting mainly the hippocampus. It is possible that part of neurotoxic effects of glucocorticoids may be due to their antagonistic effect on the neuroprotective effect of endogenous DHEA and NGF, via TrkA receptor antagonism. The decline of brain DHEA and NGF levels during aging and in Alzheimer's disease  might exacerbate this phenomenon, rendering neurons more vulnerable to glucocorticoid toxicity. Indeed, glucocorticoid neurotoxicity becomes more pronounced in aged subjects since cortisol levels in the CSF increase in the course of normal aging, as well as in relatively early stages of Alzheimer's disease .
A number of neurodegenerative conditions are associated with lower production or action of both DHEA and NGF [30, 31]. Animal studies suggest that NGF may reverse, or slow down the progression of Alzheimer's related cholinergic basal forebrain atrophy . Furthermore, the neurotrophic effects of NGF in experimental animal models of neurodegenerative conditions, like MPTP (Parkinson's disease), experimental allergic encephalomyelitis (multiple sclerosis) or ischemic retina degeneration mice [32-34] support its potential as a promising neuroprotective agent. However, the use of NGF in the treatment of these conditions is limited because of its poor brain blood barrier permeability. It is of interest that DHEA also exerts neuroprotective properties in some of these animal models [7,35]. These findings suggest that synthetic DHEA analogs, deprived of endocrine effects, may represent a new class of brain blood barrier permeable NGF receptor agonists with neuroprotective properties. We have recently reported the synthesis of 17-spiro-analogs of DHEA, with strong anti-apoptotic and neuroprotective properties, deprived of endocrine effects , which are now tested for their ability to bind and activate NGF receptors.
We have previously defined the pro-survival signaling pathways that are initiated by DHEA at the membrane level . These pathways include MEK1/2/ERK1/2, and PI3K/Akt pro-survival kinases. We now provide experimental evidence that DHEA activates these kinases via TrkA receptors (Figure 7). Downregulation of TrkA receptors using siRNAs, resulted in an almost complete reversal of the ability of DHEA to increase the phosphorylation of kinases Shc, Akt and ERK1/2. In addition to TrkA receptors, binding of DHEA to the low affinity NGF receptor was also functional, affording the activation of p75NTR receptors. Unlike TrkA receptors, p75NTR lacks any enzymatic activity. Signal transduction by p75NTR proceeds via ligand-dependent recruitment and release of cytoplasmic effectors to and from the receptor. Indeed, DHEA like NGF facilitated the recruitment of two major cytoplasmic interactors of p75NTR, TRAF6 and RIP2 proteins. Additionally, DHEA-mediated activation of p75NTR led to the dissociation of bound RhoGDI, a protein belonging to small GTPases and interacting with RhoA .
It is worth noticing that the interaction of DHEA with the NGF system was first suggested fifteen years ago by Compagnone et al, showing co-localized staining of CYP17, the rate limiting enzyme of DHEA biosynthesis, and NGF receptors in mouse embryonic DRGs . About one fifth of CYP17-immunopositive DRG neurons in the mouse were found to be also TrkA-immunopositive. Among the TrkA-expressing cells, about one third also expresses CYP17, while p75NTR-expressing neurons represent only 13% of the cells in the DRG. Thus, about one fifth of CYP17-immunopositive neurons may be able to respond to both DHEA and NGF stimulation.
Recent studies have shown the expression of CYP17 in invertebrate cephalochordata Amphioxus . Amphioxus is also expressing TrkA receptor homologous AmphiTrk, which effectively transduces signals mediated by NGF . Phylogenetic analysis of neurotrophins revealed that they emerged with the appearance of vertebrates (530-550 million years ago), when complexity of neural tissue increased . Invertebrate cephalochordata like Amphioxus are positioned on the phylogenetic boundary with vertebrates (600 million years ago). It is thus tempting to hypothesize that DHEA contributed as one of the "prehistoric" neurotrophic factors in an ancestral, simpler in structure invertebrate nervous system , then when a strict tempospatial regulation of evolving nervous system of vertebrates was needed peptidic neurotrophins emerged to afford rigorous and cell specific neurodevelopmental processes.
In conclusion, our findings suggest that DHEA and NGF cross-talk via their binding to NGF receptors to afford brain shaping and maintenance during development. During aging, the decline of both factors may leave the brain unprotected against neurotoxic challenges. This may also be the case in neurodegenerative conditions associated with lower production or action of both factors. DHEA analogs may represent lead molecules for designing non-endocrine, neuroprotective and neurogenic micromolecular NGF receptor agonists.
We thank Professor Carlos F. Ibáñez for his generous gift of TrkA, p75NTR, RIP2 (originally constructed from Dr Moses Chao), RhoGDI (originally constructed from Dr Toshihide Yamashita) and TRAF-6 (originally constructed from Dr Bruce Carter) expression plasmids. We also thank graduate students Apostolos Georgiannakis, Athanasia Pantzou and Sifis Pediaditakis for their technical assistance. This work was funded by a grant from Bionature Ltd and EmergoMed Co, and is dedicated to the memory of Professor Costas Sekeris.
IL, IC and VV performed the experiments, NA and TC synthesized the DHEA-BSA-FITC conjugate and the DHEA-NovaPEG amino resin, IC, AG designed and supervised the experiments and AG wrote the paper. AG is the co-founder of the University of Crete spin-off Bionature EA.